A recent study investigated the effects of alemtuzumab (Lemtrada) on disability measures in patients with Multiple Sclerosis (MS).
A pragmatic review of literature has identified best practices for network meta-analyses (NMAs) of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis (RRMS).
New Orleans, LA—Patients with multiple sclerosis (MS) often spend a lifetime using disease-modifying therapy (DMT). Some experts are now wondering whether some of these patients can discontinue treatment without increasing the risk for disease relapse.
Philadelphia, PA—Estriol may represent a future novel treatment option for patients with relapsing-remitting multiple sclerosis (RRMS). In a phase 2 randomized, double-blind, placebo-­controlled trial of women with RRMS, estriol, given with glatiramer acetate, reduced the relapse rate by almost 50% with only 1 year of treatment and improved cognition, reported Rhonda Voskuhl, MD, Director of the MS program, University of California, Los Angeles, at the 2014 meeting of the American Academy of Neurology.

Multiple sclerosis (MS) is the leading cause of irreversible neurologic disability in young women in the United States, and the second leading cause of neurologic disability in young men. In a series of debates at the 2016 American Academy of Neurology annual meeting, expert physicians addressed current and controversial issues in neuroscience, including the early aggressive treatment of patients with MS.

Philadelphia, PA—Extending the dosing interval of natalizumab to every 6 to 8 weeks may lower the risk for progressive multifocal leukoencephalopathy (PML) without affecting efficacy in patients with multiple sclerosis (MS).
Lifestyle physical activity should be as central to the health-promoting habits of patients with multiple sclerosis (MS) as exercise training, according to one expert.
Patients with primary and secondary progressive multiple sclerosis (MS) showed improvements in standard measures of physical and neurologic disability after taking high doses of biotin (300 mg daily) for 1 year, according to results of a phase 3 clinical trial presented at the 2015 annual meeting of the American Academy of Neurology.
Philadelphia, PA—Achieving no evidence of disease activity (NEDA) in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) is a clinically meaningful goal, but a strategy to achieve it remains untested, said Robert Bermel, MD, a neurologist at the Mellen Center for Multiple Sclerosis, the Cleveland Clinic, at the 2014 American Academy of Neurology meeting.
Philadelphia, PA—A systematic literature review conducted by the American Academy of Neurology (AAN) shows that certain forms of medical marijuana can be useful to treat some symptoms of multiple sclerosis (MS), but the evidence is insufficient to support its use in other neurologic diseases, and there are a number of safety concerns with medical marijuana.
Page 1 of 3
Results 1 - 10 of 27
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology